Brief: Allovir Announces Positive Results
26/04/2023 12:07
April 26 (Reuters) - Allovir Inc ALVR.O :
* ALLOVIR ANNOUNCES POSITIVE RESULTS INCLUDING LONG-TERM
MORTALITY
DATA IN PHASE 2 POSOLEUCEL MULTI-VIRUS PREVENTION STUDY IN ORAL
PRESENTATION AT EBMT 2023
* ALLOVIR - GLOBAL PHASE 3 PIVOTAL POSOLEUCEL TRIALS
PROGRESS WITH
ROBUST PATIENT ENROLLMENT IN US,EUROPE,ASIA WITH DATA READOUTS
ON TRACK FOR 2024
Source text for Eikon: ID:nBw2XMm2Ta
Further company coverage: ALVR.O
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million